Scholars Central

Research articlePublished 2012

Development and Clinical Trial of a Novel DNA Vaccine as Immunotherapy during Canine Leishmaniasis

Authors: Laura Manna, Ilaria Michela Piras, Valentina Ciprì, Alberto Alberti, Italia Della Peruta, Carlo Maria Del Pizzo, Nicoletta Gammarano, Elisabetta Coradduzza, Carla Cacciotto, Marco Pittau, Angelo Elio Gravino, Bernardo Chessa

Journal of Vaccines & Vaccination

Volume 3 · Issue 6 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Visceral Leishmaniasis (VL) is a zoonotic disease caused by Leishmaniainfantum in the Mediterranean area. Dogs are the main reservoir of Leishmaniainf antum parasites. Disease management represents a serious problem, since anti-Leishmania drugs have limited efficacy in both symptomatic and asymptomatic dogs, which are infective to phlebotomine vectors. In many tropical and sub-tropical countries the development of a safe and easily-available vaccine has high priority. DNA vaccines represent one of the most recent innovations in the field of immunization. Findings: This study aimed to evaluate the effect of a DNA vaccine based on two Leishmania antigens (Cpb1, PO) in leishmaniotic dogs. Twelve leishmaniotic dogs from a Leishmaniasis-endemic area (Naples, Italy) received three consecutive injections of DNA vaccine at 15-days intervals. Another group of five leishmaniotic dogs received the same amount of pVAX-1 without the coding sequences of Leishmania antigens. Leishmania DNA load, INFγ, IL-4 mRNA expression levels and clinical parameters were tested before and after the therapy, every 3 months for a period of 12 months. Analysis of the data in the vaccinated dogs showed: i) a decrease Leishmania DNA load in lymph node samples, ii) an increase of INFγ and IL-4 mRNA expression levels in PBMC samples. All vaccinated dogs also showed an improvement in the clinical symptoms. Conclusion: Our results show that the vaccine developed in this study may represent a useful tool in the treatment of leishmaniotic dogs. However, since the duration of positive effects is limited in time, further trials are needed to evaluate the effectiveness of immunotherapy alone or in association with conventional therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Laura Manna”
  • BylineArticles whose byline prints “Ilaria Michela Piras”
  • BylineArticles whose byline prints “Valentina Ciprì”
  • BylineArticles whose byline prints “Alberto Alberti”
  • BylineArticles whose byline prints “Italia Della Peruta”
  • BylineArticles whose byline prints “Carlo Maria Del Pizzo”
  • BylineArticles whose byline prints “Nicoletta Gammarano”
  • BylineArticles whose byline prints “Elisabetta Coradduzza”